IPSEN (OTCMKTS:IPSEY) Hits New 52-Week High – Should You Buy?

Shares of IPSEN (OTCMKTS:IPSEY) hit a new 52-week high on Tuesday . The stock traded as high as $48.54 and last traded at $48.54, with a volume of 402 shares traded. The stock had previously closed at $48.21.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on IPSEY shares. UBS Group downgraded IPSEN from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Tuesday, February 17th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, IPSEN has a consensus rating of “Hold”.

IPSEN Price Performance

The stock has a 50 day moving average price of $44.41 and a 200-day moving average price of $38.71.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).